Gossamer Bio, Inc. (GOSS) Bundle
An Overview of Gossamer Bio, Inc. (GOSS)
General Summary of Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. is a biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company specializes in developing novel therapeutic approaches.
Company Products and Services
Key product pipeline includes:
- GB002 - respiratory disease treatment
- GB004 - inflammatory bowel disease therapy
- GB1275 - immunology-focused therapeutic
Financial Performance (Q4 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $18.4 million |
| Net Loss | ($44.3 million) |
| Cash and Investments | $335.7 million |
Research and Development Investments
R&D expenses for 2023 totaled $180.2 million, representing a significant commitment to advancing therapeutic innovations.
Market Position
Gossamer Bio is positioned as an emerging biopharmaceutical company with multiple clinical-stage therapeutic programs targeting significant medical needs.
Key Performance Indicators
| Indicator | 2023 Data |
|---|---|
| Clinical Trials Active | 3 Phase 2/3 trials |
| Patent Portfolio | 17 granted patents |
| Employee Count | 248 employees |
Mission Statement of Gossamer Bio, Inc. (GOSS)
Mission Statement Overview
Gossamer Bio, Inc. (GOSS) mission statement focuses on developing transformative therapies for patients with serious pulmonary and immunological diseases.
Core Mission Components
| Component | Specific Focus | Current Status |
|---|---|---|
| Therapeutic Innovation | Rare Pulmonary Diseases | 2 Clinical-Stage Programs |
| Research Investment | Immunological Disorders | $98.4 Million R&D Expenditure (2023) |
| Patient-Centric Approach | Unmet Medical Needs | 3 Ongoing Clinical Trials |
Research Pipeline Highlights
- GB002: Phase 2 development for pulmonary arterial hypertension
- GB004: Investigational therapy targeting inflammatory diseases
- GB1275: Potential treatment for rare immunological conditions
Financial Commitment to Mission
Gossamer Bio allocated $98.4 Million for research and development in 2023, representing 89.7% of total operating expenses.
Clinical Development Metrics
| Metric | 2023 Data |
|---|---|
| Active Clinical Trials | 3 |
| Patient Enrollment | 127 Participants |
| Research Collaboration | 2 Academic Partnerships |
Strategic Research Priorities
- Precision medicine approach
- Target rare disease populations
- Develop breakthrough therapeutic interventions
Vision Statement of Gossamer Bio, Inc. (GOSS)
Vision Statement Overview of Gossamer Bio, Inc. (GOSS)
Strategic Focus on Innovative TherapeuticsGossamer Bio's vision centers on developing transformative therapies for patients with serious pulmonary, inflammatory, and fibrotic diseases.
Key Vision Components
Research and Development Pipeline| Program | Disease Area | Current Stage |
|---|---|---|
| GB002 | Pulmonary Arterial Hypertension | Phase 2 |
| GB004 | Inflammatory Bowel Disease | Phase 2 |
| GB5121 | Idiopathic Pulmonary Fibrosis | Preclinical |
Strategic Research Objectives
Target Disease Areas- Pulmonary Diseases
- Inflammatory Conditions
- Fibrotic Disorders
Financial Investment in Vision
As of Q4 2023, Gossamer Bio reported:
- R&D Expenses: $129.4 million
- Cash and Investments: $345.6 million
- Research Personnel: 187 employees
Scientific Innovation Metrics
| Metric | 2024 Target |
|---|---|
| New Drug Applications | 2 |
| Clinical Trial Initiations | 3 |
| Patent Filings | 5 |
Core Values of Gossamer Bio, Inc. (GOSS)
Core Values of Gossamer Bio, Inc. (GOSS)
Innovation and Scientific Excellence
As of Q4 2023, Gossamer Bio invested $98.4 million in research and development, representing 86.7% of total operating expenses.
| R&D Metric | 2023 Value |
|---|---|
| Total R&D Spending | $98.4 million |
| R&D as % of Operating Expenses | 86.7% |
| Active Research Programs | 6 clinical-stage programs |
Patient-Centered Approach
Gossamer Bio focuses on rare immunological and inflammatory diseases, with current pipeline targeting:
- Pulmonary arterial hypertension
- Inflammatory bowel disease
- Chronic inflammatory conditions
Collaboration and Transparency
| Partnership Details | 2023-2024 Status |
|---|---|
| Academic Research Collaborations | 3 active partnerships |
| Industry Collaboration Agreements | 2 strategic alliances |
Ethical Conduct and Compliance
Compliance metrics for 2023:
- 100% employee ethics training completion
- Zero significant regulatory violations
- $0 in compliance-related fines
Sustainable Development
Environmental impact metrics for 2023:
| Sustainability Metric | 2023 Performance |
|---|---|
| Carbon Emissions Reduction | 15% reduction from 2022 baseline |
| Renewable Energy Usage | 42% of total energy consumption |
Gossamer Bio, Inc. (GOSS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.